Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT06291025 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

131

Enrollment

OTHER

Sponsor class

Conditions

Thrombotic Microangiopathies

Interventions

PROCEDURE: PEX-FREE

Sponsor

University Hospital, Rouen